HEC169096 in Participants With Advanced Solid Tumors

StatusTerminated
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: Sponsor strategic decision; the study will not continue. Show 4 more changesShow less
    • Final enrollment: 24 participants — 5% of the 456 planned
    • Primary completion date changed from estimate of Dec 30, 2026 to Sep 23, 2025
    • Eligibility criteria expanded, about 24 words
    • Site details revised
  2. Primary completion date: Jul 30, 2025 to Dec 30, 2026v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Enrollment target: 376 to 456
    • Start date changed from estimate of Aug 20, 2022 to Oct 21, 2022
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of HEC169096 In Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors.
Trial Details
NCT Number NCT05451602
Lead Sponsor Sunshine Lake Pharma Co., Ltd.
Conditions
(from sponsor)		 Advanced Solid Tumor
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov